Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

Cited In for PubMed (Select 8810340)

1.

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity.

Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB, Cavenee WK.

Cancer Res. 2014 Mar 1;74(5):1429-39. doi: 10.1158/0008-5472.CAN-13-2117. Epub 2014 Jan 16.

2.

Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.

Kastenhuber ER, Huse JT, Berman SH, Pedraza A, Zhang J, Suehara Y, Viale A, Cavatore M, Heguy A, Szerlip N, Ladanyi M, Brennan CW.

Acta Neuropathol. 2014 May;127(5):747-59. doi: 10.1007/s00401-013-1217-3. Epub 2013 Nov 29.

3.

Bayesian methods for expression-based integration of various types of genomics data.

Jennings EM, Morris JS, Carroll RJ, Manyam GC, Baladandayuthapani V.

EURASIP J Bioinform Syst Biol. 2013 Sep 21;2013(1):13. doi: 10.1186/1687-4153-2013-13.

4.

Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.

Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, Gordon W, Lauffenburger DA, Fraenkel E.

PLoS Comput Biol. 2013;9(2):e1002887. doi: 10.1371/journal.pcbi.1002887. Epub 2013 Feb 7.

5.

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.

Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB.

Oncogene. 2012 Sep 6;31(36):4054-66. doi: 10.1038/onc.2011.563. Epub 2011 Dec 5.

6.

Innovative Therapies against Human Glioblastoma Multiforme.

Cimini A, Ippoliti R.

ISRN Oncol. 2011;2011:787490. doi: 10.5402/2011/787490. Epub 2011 Jul 24.

7.

Forced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.

Hwang Y, Chumbalkar V, Latha K, Bogler O.

Mol Cancer Res. 2011 Sep;9(9):1199-208. doi: 10.1158/1541-7786.MCR-11-0229. Epub 2011 Jul 20.

8.
9.

Drosophila melanogaster as a model system for human brain cancers.

Read RD.

Glia. 2011 Sep;59(9):1364-76. doi: 10.1002/glia.21148. Epub 2011 May 2. Review.

10.

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, Zhang T, Ludkovski O, Wang L, Chen EX, Tsao MS, Kamel-Reid S, Siu LL.

Head Neck Oncol. 2011 Feb 27;3:11. doi: 10.1186/1758-3284-3-11.

11.

Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance.

Hatanpaa KJ, Burma S, Zhao D, Habib AA.

Neoplasia. 2010 Sep;12(9):675-84. Review.

12.

Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth.

Huang PH, Miraldi ER, Xu AM, Kundukulam VA, Del Rosario AM, Flynn RA, Cavenee WK, Furnari FB, White FM.

Mol Biosyst. 2010 Jul;6(7):1227-37. doi: 10.1039/c001196g. Epub 2010 May 11.

13.

EPS8 upregulates FOXM1 expression, enhancing cell growth and motility.

Wang H, Teh MT, Ji Y, Patel V, Firouzabadian S, Patel AA, Gutkind JS, Yeudall WA.

Carcinogenesis. 2010 Jun;31(6):1132-41. doi: 10.1093/carcin/bgq058. Epub 2010 Mar 29.

14.

Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes.

Lo HW, Cao X, Zhu H, Ali-Osman F.

Mol Cancer Res. 2010 Feb;8(2):232-45. doi: 10.1158/1541-7786.MCR-09-0391. Epub 2010 Feb 9.

15.
16.

Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Thaker NG, Pollack IF.

Expert Rev Neurother. 2009 Dec;9(12):1815-36. doi: 10.1586/ern.09.116. Review.

17.

EGFRvIII-targeted vaccination therapy of malignant glioma.

Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH.

Brain Pathol. 2009 Oct;19(4):713-23. doi: 10.1111/j.1750-3639.2009.00318.x. Review.

18.

Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity.

Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, Tindall DJ, Farassati F.

Mol Cancer Ther. 2008 Nov;7(11):3586-97. doi: 10.1158/1535-7163.MCT-08-0653.

19.

Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Plati J, Bucur O, Khosravi-Far R.

J Cell Biochem. 2008 Jul 1;104(4):1124-49. doi: 10.1002/jcb.21707. Review.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk